Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice—making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research.
Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies.
Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies.
Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts.
Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
1. Introduction - p. 41 2. Complement activation pathways - p. 42 3. Complement effector molecules - p. 44 4. Complement therapeutics - p. 46 5. Complement response to cancer - p. 48 6. Complement dependent cytotoxicity and cancer - p. 49 7. Complement regulatory proteins and cancer - p. 50 8. Complement activation in the tumor microenvironment enhances tumor growth - p. 51 9. The role of complement activation in cancer progression - p. 55 10. Potential application of anticomplement cancer therapies (C3aR/C5aR/IL-10 pathway) - p. 57 11. Conclusions - p. 58 12. Key references - p. 59 13. References - p. 60.e1 14. 4. Cancer and the science of innate immunity - p. 61 15. Introduction - p. 61 16. The cellular components of the innate immune response - p. 61 17. Innate immune networks in the promotion of tumor growth, immune suppression, and metastasis - p. 72 18. Innate immune sensing during cancer progression - p. 83 19. Cancer therapies targeting innate immunity - p. 85 20. Key references - p. 88 21. References - p. 90.e1 22. 5. Tumor antigenicity and cancer as non-self - p. 91 23. 6. Tumor immune surveillance - p. 115 24. 7. The essential elements of adaptive immunity and their relevance to cancer immunology - p. 129 25. 8. Cancer—avoiding immune detection - p. 157 26. 9. Vaccines and active immunization against cancer - p. 177 27. 10. The major clinical components of cancer immunotherapy (modulating cell-mediated immune mechanisms) - p. 195 28. 11. The microbiome and cancer immunotherapy - p. 223 29. 12. The clinical application of immuno-therapeutics - p. 237 30. Introduction - p. 237 31. Historical background - p. 237 32. General classes of cancer immunotherapy agents - p. 238 33. Skin cancer - p. 238 34. Lung cancer - p. 245 35. Triple-negative breast cancer - p. 254 36. Gastrointestinal malignancies - p. 255 37. Gynecologic malignancies - p. 264 38. Genitourinary malignancies - p. 267 39. Prostate cancer - p. 273 40. Head and neck squamous cell carcinoma - p. 274 41. Tissue/site-agnostic malignant solid tumors - p. 276 42. Hematologic malignancies - p. 276 43. Immune-related toxicities associated with checkpoint blockade - p. 283 44. Toxicities associated with CAR T-cell therapy - p. 285 45. Prospective directions - p. 286 46. Key references - p. 287 47. References - p. 288.e1 48. 13. The effect of COVID-19 on cancer immunotherapy and cancer care - p. 289 49. Index - p. 311
Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice—making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research.
Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies.
Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies.
Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts.
Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.
1. Introduction - p. 41 2. Complement activation pathways - p. 42 3. Complement effector molecules - p. 44 4. Complement therapeutics - p. 46 5. Complement response to cancer - p. 48 6. Complement dependent cytotoxicity and cancer - p. 49 7. Complement regulatory proteins and cancer - p. 50 8. Complement activation in the tumor microenvironment enhances tumor growth - p. 51 9. The role of complement activation in cancer progression - p. 55 10. Potential application of anticomplement cancer therapies (C3aR/C5aR/IL-10 pathway) - p. 57 11. Conclusions - p. 58 12. Key references - p. 59 13. References - p. 60.e1 14. 4. Cancer and the science of innate immunity - p. 61 15. Introduction - p. 61 16. The cellular components of the innate immune response - p. 61 17. Innate immune networks in the promotion of tumor growth, immune suppression, and metastasis - p. 72 18. Innate immune sensing during cancer progression - p. 83 19. Cancer therapies targeting innate immunity - p. 85 20. Key references - p. 88 21. References - p. 90.e1 22. 5. Tumor antigenicity and cancer as non-self - p. 91 23. 6. Tumor immune surveillance - p. 115 24. 7. The essential elements of adaptive immunity and their relevance to cancer immunology - p. 129 25. 8. Cancer—avoiding immune detection - p. 157 26. 9. Vaccines and active immunization against cancer - p. 177 27. 10. The major clinical components of cancer immunotherapy (modulating cell-mediated immune mechanisms) - p. 195 28. 11. The microbiome and cancer immunotherapy - p. 223 29. 12. The clinical application of immuno-therapeutics - p. 237 30. Introduction - p. 237 31. Historical background - p. 237 32. General classes of cancer immunotherapy agents - p. 238 33. Skin cancer - p. 238 34. Lung cancer - p. 245 35. Triple-negative breast cancer - p. 254 36. Gastrointestinal malignancies - p. 255 37. Gynecologic malignancies - p. 264 38. Genitourinary malignancies - p. 267 39. Prostate cancer - p. 273 40. Head and neck squamous cell carcinoma - p. 274 41. Tissue/site-agnostic malignant solid tumors - p. 276 42. Hematologic malignancies - p. 276 43. Immune-related toxicities associated with checkpoint blockade - p. 283 44. Toxicities associated with CAR T-cell therapy - p. 285 45. Prospective directions - p. 286 46. Key references - p. 287 47. References - p. 288.e1 48. 13. The effect of COVID-19 on cancer immunotherapy and cancer care - p. 289 49. Index - p. 311
